Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data

被引：0

作者：

Wolinsky, Jerry S. ^{[1
]}

Brochet, Bruno ^{[2
]}

Hartung, Hans-Peter ^{[3
,4
]}

Naismith, Robert T. ^{[5
]}

Airas, Laura ^{[6
]}

Coutant, Karine ^{[7
]}

Koendgen, Harold ^{[7
]}

Manfrini, Marianna ^{[7
]}

Overell, James ^{[7
]}

Sauter, Annette ^{[7
]}

Prajapati, Kalpesh ^{[8
]}

Kappos, Ludwig ^{[9
]}

机构：

[1] Univ Texas Hlth Sci Ctr Houston UTHlth, McGovern Med Sch, Houston, TX USA

[2] Univ Bordeaux, Bordeaux, France

[3] Heinrich Heine Univ Dusseldorf, Ctr Neurol & Neuropsychiat, UKD, Dept Neurol, Dusseldorf, Germany

[4] Heinrich Heine Univ Dusseldorf, LVR Klinikum, Dusseldorf, Germany

[5] Washington Univ, Sch Med, St Louis, MO 14263 USA

[6] Univ Turku, Div Clin Neurosci, Turku, Finland

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] GCE Solut Inc, Bloomington, IL USA

[9] Univ Basel, Univ Hosp Basel, Basel, Switzerland

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1807

引用

页数：4

共 50 条

[1] Sustained Reduction In Confirmed Disability Progression In Primary Progressive Ms Patients Treated With Ocrelizumab: 6.5-study Year Follow-up Data
Wolinsky, J. S.
Brochet, B.
Hartung, H.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Manfrini, M.
Wang, Q.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 49 - 50
[2] Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data
Wolinsky, J. S.
Brochet, B.
Hartung, H. -P.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Manfrini, M.
Mehta, L.
Prajapati, K.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 56 - 57
[3] Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
Wolinsky, J. S.
Brochet, B.
Hartung, H. P.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Manfrini, M.
Mehta, L.
Prajapati, K.
Kappos, L.
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
[4] Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the ORATORIO OLE: 8-year follow-up
Wolinsky, J. S.
Vermersch, P.
Hartung, H. -P.
Naismith, R. T.
Airas, L.
Townsend, B.
Schneble, H. -M.
Overell, J.
Sauter, A.
Wang, Q.
Prajapati, K.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 101 - 102
[5] Sustained reduction in 48-week confirmed disability progression in patients with ppms treated with ocrelizumab in the oratorio ole: 7-year follow-up
Wolinsky, J.
Vermersch, P.
Hartung, H. P.
Naismith, R. T.
Airas, L.
Coutant, K.
Koendgen, H.
Schneble, H. -M.
Overell, J.
Sauter, A.
Prajapati, K.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 234 - 235
[6] Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
Wolisnky, J. S.
Brochet, B.
Montalban, X.
Naismith, R. T.
Manfrini, M.
Garas, M.
Villoslada, P.
Model, F.
Hubeaux, S.
Kappos, L.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 490 - 491
[7] Real-world data of ocrelizumab effects on disability progression; A 2-year follow-up study
Baba, C.
Kaya, E.
Ozcelik, S.
Ozdogar, A. T.
Sagici, O.
Dastan, S.
Ozakbas, S.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 860 - 860
[8] Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period
Wolinsky, J. S.
Montalban, X.
Hauser, S. L.
Model, F.
Deol-Bhullar, G.
Garren, H.
Kappos, L.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 656 - 657
[9] Ocrelizumab in an expanded cohort of primary progressive MS patients: safety outcomes and clinical/paraclinical follow-up
Novi, G.
Cellerino, M.
Nesi, L.
Sbragia, E.
Lapucci, C.
Laroni, A.
Roccatagliata, L.
Sormani, M. P.
Inglese, M.
Uccelli, A.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 901 - 902
[10] Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis
Wolinsky, Jerry S.
Kappos, Ludwig
Montalban, Xavier
Model, Fabian
Mehta, Lahar
Hubeaux, Stanislas
Giovannoni, Gavin
NEUROLOGY, 2019, 92 (15)

← 1 2 3 4 5 →